ConductScience.org, home

Paper42877652PubMed

COVID-19 disease: novel clinical manifestations and therapeutic exploration.

Liu C and 9 others. Arch Med Sci, 2026.

Cite this record

ConductScience Library. COVID-19 disease: novel clinical manifestations and therapeutic exploration. Papers, record 42877652. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42877652

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
COVID-19 disease: novel clinical manifestations and therapeutic exploration.
Journal
Arch Med Sci
Year
2026
Publication types
Journal Article
Revised in PubMed
2026-10-15

Source PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu CChun
2Huang QQiang
3Wang PPingXi
4Wu HHuaPing
5Deng SShuKai
6Liu DDan
7Xiang CChunFeng
8Gao QQiang
9Zeng FFanWei
10Zheng XXiangDe

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130831481The value of FDP/FIB and D-dimer/FIB ratios in predicting high-risk APL-related thrombosis.Leuk Res2019https://conductscience.org/library/papers/30831481PubMed
231736922Dynamic Changes in the Microbiome and Mucosal Immune Microenvironment of the Lower Respiratory Tract by Influenza Virus Infection.Front Microbiol2019https://conductscience.org/library/papers/31736922PubMed
332114193Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests.Int J Infect Dis2020https://conductscience.org/library/papers/32114193PubMed
432109013Clinical Characteristics of Coronavirus Disease 2019 in China.N Engl J Med2020https://conductscience.org/library/papers/32109013PubMed
532171076Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.Lancet2020https://conductscience.org/library/papers/32171076PubMed
632399094Statins and the COVID-19 main protease: in silico evidence on direct interaction.Arch Med Sci2020https://conductscience.org/library/papers/32399094PubMed
729052924MERS, SARS and other coronaviruses as causes of pneumonia.Respirology2018https://conductscience.org/library/papers/29052924PubMed
832098422Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV.Viruses2020https://conductscience.org/library/papers/32098422PubMed
931110978Clinical Significance of Detection of Coagulation Indexes, Immune Factors and Inflammatory Factors in Patients with Pregnancy-Induced Hypertension Syndrome in China.Iran J Public Health2019https://conductscience.org/library/papers/31110978PubMed
1032399093Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.Arch Med Sci2020https://conductscience.org/library/papers/32399093PubMed
1132120458[Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV].Zhonghua Xin Xue Guan Bing Za Zhi2020https://conductscience.org/library/papers/32120458PubMed
1226847650Molecular mechanisms of coronavirus RNA capping and methylation.Virol Sin2016https://conductscience.org/library/papers/26847650PubMed
1332309622Emerging Therapeutic Strategies for COVID-19 patients.Discoveries (Craiova)2020https://conductscience.org/library/papers/32309622PubMed
1432187464A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.N Engl J Med2020https://conductscience.org/library/papers/32187464PubMed
1532125642Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools.Virol Sin2020https://conductscience.org/library/papers/32125642PubMed
1632100877Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2.J Med Virol2020https://conductscience.org/library/papers/32100877PubMed
1731978945A Novel Coronavirus from Patients with Pneumonia in China, 2019.N Engl J Med2020https://conductscience.org/library/papers/31978945PubMed
1817326933Review of bats and SARS.Emerg Infect Dis2006https://conductscience.org/library/papers/17326933PubMed
1932124995Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia.J Med Virol2020https://conductscience.org/library/papers/32124995PubMed
2024172901Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor.Nature2013https://conductscience.org/library/papers/24172901PubMed

See all 32 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42877652

GET https://conductscience.org/api/papers/v1/42877652/references?page=2